anticoagulants, oral direct thrombin inhibitors, dabigatran, patients who had serious bleeding or required an urgent procedure
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2015 Aug 6;373(6):511-20 Cohorts
IN anticoagulants, oral direct thrombin inhibitors, dabigatran, patients who had serious bleeding or required an urgent procedure The Use of
idarucizumab, an dabigatran-specific antibody fragment
As Treatment, Acute
Is better Than
no comparison done
To normalize hemostasis tests in 88 to 98% of the patients in minutes. One thrombotic event occurred within 72 hours after idarucizumab administration.